New Study on CMT Type 2B

by | Feb 12, 2014 | 5 comments

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver.  A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs. This cross sectional study used several standard questionnaires to survey 123 patients enrolled through clinical and genetic testing. It suggested not surprisingly that patients believe it is important to feel better after physical therapy. There was also a discrepancy between the perception of benefit from rehabilitation for the patient, versus the caregiver’s perception of benefit.

When we think of animal models for diseases like CMT, probably the fly is the furthest from our mind. Yet the humble fly may have overturned our basic understanding of the disease mechanism behind CMT2B becoming the first animal model for this disease. For CMT2B it was long thought to be a gain of function disease. A recent study by Cherry and co-workers at the University of Texas Southwestern Medical Center, show that neurons lacking a gene for rab7 result in neuropathy, while addition of Rab7 proteins could return function. Such insights can affect how we approach trying to find a cure for the disease, perhaps methods to increase Rab7 proteins while opposite to the previous dogma, may actually be right. There are still hurdles to overcome because the fly may not be a perfect model for human CMT2B.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Join the conversation

Leave a Comment


  1. Kelly

    The biggest question that needs to be answered is why does Rab7 function normally throughout the rest of the body. Rab7 is ubiquitous. Rab7 only has a problem in the extremities; hands and feet. I have CMT 2B. My family is the only one in America so far with this rare disease. I keep tabs on the research being done because I am hoping for a cure. I would be interested in speaking to anyone who wants more information or someone who has more information. Thanks.

    • Matt Scesney

      Kelly, my wife and her family have CMT Type 2B and we’re diagnosed 17 years ago at UCLA. My wife has lost bladder and bowel function resulting in a interstem implant. She also has the typical atrophy in her extremities and Adees pupils and on and on.

    • Matt Scesney

      My wife has type 2B with gross mutations as does her mother and brother. We live in California.

      • Kelly Mhic Threanfhir

        Hi, Matt, sorry I didn’t see this sooner. I just saw it. Please email me at [email protected] I would love to talk to you! So far my family is the only family in America that has been diagnosed with CMT 2B. There are 11 families listed in the world that have it. I don’t think your wife’s family is on the list, so it would be good to sort that out as her family would be second one diagnosed in USA.


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news